Literature DB >> 32472710

The 3Ds in virus-like particle based-vaccines: "Design, Delivery and Dynamics".

Mona O Mohsen1,2, Gilles Augusto2,3, Martin F Bachmann2,3.   

Abstract

Vaccines need to be rationally designed in order be delivered to the immune system for maximizing induction of dynamic immune responses. Virus-like particles (VLPs) are ideal platforms for such 3D vaccines, as they allow the display of complex and native antigens in a highly repetitive form on their surface and can easily reach lymphoid organs in intact form for optimal activation of B and T cells. Adjusting size and zeta potential may allow investigators to further fine-tune delivery to lymphoid organs. An additional way to alter vaccine transfer to lymph nodes and spleen may be the formulation with micron-sized adjuvants that creates a local depot and results in a slow release of antigen and adjuvant. Ideally, the adjuvant in addition stimulates the innate immune system. The dynamics of the immune response may be further enhanced by inclusion of Toll-like receptor ligands, which many VLPs naturally package. Hence, considering the 3Ds in vaccine development may allow for enhancement of their attributes to tackle complex diseases, not usually amenable to conventional vaccine strategies.
© 2020 The Authors. Immunological Reviews published by John Wiley & Sons Ltd.

Entities:  

Keywords:  delivery; design; dynamics; vaccine; virus-like particles

Year:  2020        PMID: 32472710     DOI: 10.1111/imr.12863

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  21 in total

Review 1.  Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.

Authors:  Chiara Rinoldi; Seyed Shahrooz Zargarian; Pawel Nakielski; Xiaoran Li; Anna Liguori; Francesca Petronella; Dario Presutti; Qiusheng Wang; Marco Costantini; Luciano De Sio; Chiara Gualandi; Bin Ding; Filippo Pierini
Journal:  Small Methods       Date:  2021-07-28

Review 2.  Virus Structures and Dynamics by Magic-Angle Spinning NMR.

Authors:  Gal Porat-Dahlerbruch; Amir Goldbourt; Tatyana Polenova
Journal:  Annu Rev Virol       Date:  2021-09-29       Impact factor: 10.431

3.  B and Th cell response to Ag in vivo: Implications for vaccine development and diseases.

Authors:  Richard B Kennedy; Irina Grigorova
Journal:  Immunol Rev       Date:  2020-07       Impact factor: 10.983

Review 4.  Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT®).

Authors:  Matthew D Heath; Mona O Mohsen; Pieter-Jan de Kam; Thalia L Carreno Velazquez; Simon J Hewings; Matthias F Kramer; Thomas M Kündig; Martin F Bachmann; Murray A Skinner
Journal:  Front Immunol       Date:  2020-11-24       Impact factor: 7.561

5.  Recombinant Baculovirus-Produced Grass Carp Reovirus Virus-Like Particles as Vaccine Candidate That Provides Protective Immunity against GCRV Genotype II Infection in Grass Carp.

Authors:  Ting Gao; Caixia Gao; Siyu Wu; Yingying Wang; Jiyuan Yin; Yingying Li; Weiwei Zeng; Sven M Bergmann; Qing Wang
Journal:  Vaccines (Basel)       Date:  2021-01-14

6.  A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development.

Authors:  Yingzhu Li; Rumiana Tenchov; Jeffrey Smoot; Cynthia Liu; Steven Watkins; Qiongqiong Zhou
Journal:  ACS Cent Sci       Date:  2021-03-29       Impact factor: 14.553

7.  AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate.

Authors:  Xuelan Liu; Xinyue Chang; Dominik Rothen; Mariliza Derveni; Pascal Krenger; Salony Roongta; Edward Wright; Monique Vogel; Kaspars Tars; Mona O Mohsen; Martin F Bachmann
Journal:  Vaccines (Basel)       Date:  2021-04-19

8.  Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles.

Authors:  Lisha Zha; Xinyue Chang; Hongxin Zhao; Mona O Mohsen; Liang Hong; Yuhang Zhou; Hongquan Chen; Xuelan Liu; Jie Zhang; Dong Li; Ke Wu; Byron Martina; Junfeng Wang; Monique Vogel; Martin F Bachmann
Journal:  Vaccines (Basel)       Date:  2021-04-16

Review 9.  VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants.

Authors:  Wasim A Prates-Syed; Lorena C S Chaves; Karin P Crema; Larissa Vuitika; Aline Lira; Nelson Côrtes; Victor Kersten; Francisco E G Guimarães; Mohammad Sadraeian; Fernando L Barroso da Silva; Otávio Cabral-Marques; José A M Barbuto; Momtchilo Russo; Niels O S Câmara; Gustavo Cabral-Miranda
Journal:  Vaccines (Basel)       Date:  2021-11-30

10.  Chimeric RHDV Virus-Like Particles Displaying Foot-and-Mouth Disease Virus Epitopes Elicit Neutralizing Antibodies and Confer Partial Protection in Pigs.

Authors:  Giselle Rangel; Juan Bárcena; Noelia Moreno; Carlos P Mata; José R Castón; Alí Alejo; Esther Blanco
Journal:  Vaccines (Basel)       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.